Reduction of Hematopoietic Cell-specific Tyrosine Phosphatase SHP-1 Gene Expression in Natural Killer Cell Lymphoma and Various Types of Lymphomas/leukemias : Combination Analysis with CDNA Expression Array and Tissue Microarray

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2001 Oct 5

PMID 11583976

Citations 45

Authors

T Oka

T Yoshino

K Hayashi

N Ohara

T Nakanishi

Y Yamaai

A Hiraki

C A Sogawa

E Kondo

N Teramoto

K Takahashi

J Tsuchiyama

T Akagi

Affiliations

Soon will be listed here.

Abstract

To investigate the lymphomagenesis of NK/T lymphoma, we comprehensively and systematically analyzed the expression pattern of the human NK/T cell line (NK-YS) genome by cDNA expression array and tissue microarray. We detected significant changes in the gene expression of NK-YS cell line: an increase in 18 and a decrease in 20 genes compared to normal NK cells or peripheral blood mononuclear cells. Among these genes, we found a strong decrease in hematopoietic cell specific protein-tyrosine-phosphatase SH-PTP1 (SHP1) mRNA by cDNA expression array and reverse transcriptase-polymerase chain reaction. Further analysis with standard immunohistochemistry and tissue microarray, which used 207 paraffin-embedded specimens of various kinds of malignant lymphomas, showed that 100% of NK/T lymphoma specimens and more than 95% of various types of malignant lymphoma were negative for SHP1 protein expression. On the other hand, SHP1 protein was strongly expressed in the mantle zone and interfollicular zone lymphocytes in reactive lymphoid hyperplasia specimens. In addition, various kinds of hematopoietic cell lines, particularly the highly aggressive lymphoma/leukemia lines, lacked SHP1 expression in vitro, suggesting that loss of SHP1 expression may be related to not only malignant transformation, but also tumor cell aggressiveness. SHP1 expression could not be induced in either of two NK/T cell lines by phorbol ester, suggesting that genetic impairment or modification with methylation of SHP1 DNA could be one of the critical events in the pathogenesis of NK/T lymphoma. This evidence strongly suggests that loss of SHP1 gene expression plays an important role in multistep tumorigenesis, possibly as an anti-oncogene in the wide range of lymphomas/leukemias as well as NK/T lymphomas.

Citing Articles

JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β.

Aoun C, Maslah N, Ganesan S, Salomao N, Gendron R, Awan Toor S J Cell Mol Med. 2024; 28(20):e70138.

PMID: 39431551 PMC: 11492149. DOI: 10.1111/jcmm.70138.

Synthesis and Biological Evaluation of 3-Amino-4,4-Dimethyl Lithocholic Acid Derivatives as Novel, Selective, and Cellularly Active Allosteric SHP1 Activators.

Chen H, Liu Z, Gao L, Yu L, Zhou Y, Tang J Molecules. 2023; 28(6).

PMID: 36985458 PMC: 10056611. DOI: 10.3390/molecules28062488.

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.

Chen J, Chu P, Huang C, Huang T, Wang W, Lee Y Mol Med. 2022; 28(1):93.

PMID: 35941532 PMC: 9358803. DOI: 10.1186/s10020-022-00518-0.

PTPN6-EGFR Protein Complex: A Novel Target for Colon Cancer Metastasis.

Liu G, Zhang Y, Huang Y, Yuan X, Cao Z, Zhao Z J Oncol. 2022; 2022:7391069.

PMID: 35186080 PMC: 8856819. DOI: 10.1155/2022/7391069.

Epigenetics in psoriasis: perspective of DNA methylation.

Luo Y, Qu K, Kuai L, Ru Y, Huang K, Yan X Mol Genet Genomics. 2021; 296(5):1027-1040.

PMID: 34137900 DOI: 10.1007/s00438-021-01804-y.

References

Fusaki N, Tomita S, Wu Y, Okamoto N, Goitsuka R, Kitamura D . BLNK is associated with the CD72/SHP-1/Grb2 complex in the WEHI231 cell line after membrane IgM cross-linking. Eur J Immunol. 2000; 30(5):1326-30. DOI: 10.1002/(SICI)1521-4141(200005)30:5<1326::AID-IMMU1326>3.0.CO;2-Q. View

Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S . Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4(7):844-7. DOI: 10.1038/nm0798-844. View

Towbin H, Staehelin T, Gordon J . Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979; 76(9):4350-4. PMC: 411572. DOI: 10.1073/pnas.76.9.4350. View

Siminovitch K, Neel B . Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases. Semin Immunol. 1998; 10(4):329-47. DOI: 10.1006/smim.1998.0125. View

Tsuchiyama J, Yoshino T, Mori M, Kondoh E, Oka T, Akagi T . Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood. 1998; 92(4):1374-83. View

Wu Y, Nadler M, Brennan L, Gish G, Timms J, Fusaki N . The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1. Curr Biol. 1998; 8(18):1009-17. DOI: 10.1016/s0960-9822(07)00421-6. View

Binstadt B, Billadeau D, Jevremovic D, Williams B, Fang N, Yi T . SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors. J Biol Chem. 1998; 273(42):27518-23. DOI: 10.1074/jbc.273.42.27518. View

Blasioli J, Paust S, Thomas M . Definition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22. J Biol Chem. 1999; 274(4):2303-7. DOI: 10.1074/jbc.274.4.2303. View

Duggan D, Bittner M, Chen Y, Meltzer P, Trent J . Expression profiling using cDNA microarrays. Nat Genet. 1999; 21(1 Suppl):10-4. DOI: 10.1038/4434. View

10.

Wang L, Blasioli J, Plas D, Thomas M, Yokoyama W . Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B. J Immunol. 1999; 162(3):1318-23. View

11.

Dustin L, Plas D, Wong J, Hu Y, Soto C, Chan A . Expression of dominant-negative src-homology domain 2-containing protein tyrosine phosphatase-1 results in increased Syk tyrosine kinase activity and B cell activation. J Immunol. 1999; 162(5):2717-24. View

12.

Wang K, Gan L, Jeffery E, Gayle M, Gown A, Skelly M . Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene. 1999; 229(1-2):101-8. DOI: 10.1016/s0378-1119(99)00035-9. View

13.

Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T . High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999; 154(4):981-6. PMC: 1866554. DOI: 10.1016/S0002-9440(10)65349-7. View

14.

Long E . Regulation of immune responses through inhibitory receptors. Annu Rev Immunol. 1999; 17:875-904. DOI: 10.1146/annurev.immunol.17.1.875. View

15.

Siminovitch K, Lamhonwah A, Somani A, Cardiff R, Mills G . Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation. Curr Top Microbiol Immunol. 1999; 246:291-7; discussion 298. DOI: 10.1007/978-3-642-60162-0_36. View

16.

Cornall R, Goodnow C, Cyster J . Regulation of B cell antigen receptor signaling by the Lyn/CD22/SHP1 pathway. Curr Top Microbiol Immunol. 1999; 244:57-68. DOI: 10.1007/978-3-642-58537-1_5. View

17.

Brockdorff J, Williams S, Couture C, Mustelin T . Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1. Eur J Immunol. 1999; 29(8):2539-50. DOI: 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M. View

18.

Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A . Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999; 5(8):1966-75. View

19.

Bittorf T, Seiler J, Zhang Z, Jaster R, Brock J . SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. Biol Chem. 1999; 380(10):1201-9. DOI: 10.1515/BC.1999.152. View

20.

BLERY M, Olcese L, Vivier E . Early signaling via inhibitory and activating NK receptors. Hum Immunol. 2000; 61(1):51-64. DOI: 10.1016/s0198-8859(99)00157-3. View